HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 243 filers reported holding HAEMONETICS CORP in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,867 | -12.8% | 32,000 | -17.2% | 0.07% | +1.5% |
| Q2 2023 | $3,289 | -3.7% | 38,625 | -6.4% | 0.07% | -16.2% |
| Q1 2023 | $3,416 | +55.1% | 41,278 | +47.4% | 0.08% | +29.0% |
| Q4 2022 | $2,202 | -99.9% | 28,000 | +10.5% | 0.06% | +24.0% |
| Q3 2022 | $1,877,000 | +74.6% | 25,350 | +53.6% | 0.05% | +56.2% |
| Q2 2022 | $1,075,000 | +13.3% | 16,500 | +10.0% | 0.03% | +45.5% |
| Q1 2022 | $949,000 | -0.1% | 15,004 | -16.2% | 0.02% | +4.8% |
| Q4 2021 | $950,000 | -22.0% | 17,908 | +3.8% | 0.02% | -19.2% |
| Q3 2021 | $1,218,000 | +21.8% | 17,255 | +15.0% | 0.03% | +18.2% |
| Q2 2021 | $1,000,000 | +68.4% | 15,000 | +200.0% | 0.02% | +100.0% |
| Q4 2020 | $594,000 | -33.0% | 5,000 | -50.8% | 0.01% | -54.2% |
| Q3 2020 | $887,000 | -1.4% | 10,164 | +1.1% | 0.02% | -7.7% |
| Q2 2020 | $900,000 | +311.0% | 10,050 | +92.9% | 0.03% | +420.0% |
| Q4 2013 | $219,000 | -59.6% | 5,210 | -61.7% | 0.01% | -16.7% |
| Q3 2013 | $542,000 | – | 13,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |